COPD

News

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

News

In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.

News

AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.

News

GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.

News

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.

News

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.